A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Motixafortide identity.
Showing the latest 17 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 16, 2026.
PeptideScanner retained ClinicalTrials.gov record NCT04543071 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was motixafortide.
PeptideScanner retained ClinicalTrials.gov record NCT05618301 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-11, and PeptideScanner's reviewed identity mapping was motixafortide.
PeptideScanner retained ClinicalTrials.gov record NCT06442761 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was motixafortide.
PeptideScanner retained ClinicalTrials.gov record NCT06506461 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was motixafortide.
PeptideScanner retained ClinicalTrials.gov record NCT06547112 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-29, and PeptideScanner's reviewed identity mapping was motixafortide.
PeptideScanner retained ClinicalTrials.gov record NCT07101445 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was motixafortide.
PeptideScanner retained ClinicalTrials.gov record NCT07392970 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was motixafortide.
The official Drugs@FDA dataset lists original submission 1 for NDA 217159 with status AP dated 2023-09-08, and names motixafortide acetate among the application record's active ingredients.
PubMed lists PMID 34253578 in Clinical cancer research : an official journal of the American Association for Cancer Research as Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-07-12 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 36901829 in International journal of molecular sciences as Journal Article, with publication-date metadata of 2023-02-23 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 37069359 in Nature medicine as Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Journal Article, Research Support, N.I.H., Extramural, and 1 more PubMed publication type, with publication-date metadata of 2023-04-17 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 37862457 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2024-01-01 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38629183 in Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners as Journal Article, Comparative Study, Review, with publication-date metadata of 2024-04-17 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 40420423 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2025-07 (month precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 41741368 in The oncologist as Journal Article, Clinical Trial, Phase I, Randomized Controlled Trial, Clinical Trial, Phase II, with publication-date metadata of 2026-03-09 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42435378 in Transfusion as Journal Article, with publication-date metadata of 2026-07-11 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42811017 in Nature communications as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-08-21 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.